Your browser doesn't support javascript.
loading
Long-term health care resource and cost savings with allergy immunotherapy: REACT study results.
Fritzsching, Benedikt; Porsbjerg, Celeste; Contoli, Marco; Buchs, Sarah; Larsen, Julie Rask; Freemantle, Nick.
Afiliación
  • Fritzsching B; Paediatric Pulmonology and Allergy, Children's Doctor Service, Heidelberg, Germany.
  • Porsbjerg C; Department of Respiratory Medicine, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.
  • Contoli M; Respiratory Section, Department of Translational Medicine, University of Ferrara, Ferrara, Italy.
  • Buchs S; Global Market Access, ALK-Abelló, Hørsholm, Denmark.
  • Larsen JR; Global Medical Affairs, ALK-Abelló, Hørsholm, Denmark.
  • Freemantle N; Institute of Clinical Trials and Methodology, University College London, London, United Kingdom.
J Allergy Clin Immunol Glob ; 3(1): 100197, 2024 Feb.
Article en En | MEDLINE | ID: mdl-38226187
ABSTRACT

Background:

Allergy immunotherapy (AIT) can be administered as subcutaneous immunotherapy (SCIT) injections in the clinic or as sublingual immunotherapy (SLIT) tablets at home after initiation under medical supervision. To achieve long-term, sustained effects, a 3-year treatment duration is recommended.

Objective:

Our aim was to assess the association of AIT (SCIT and SLIT tablets) with long-term health care resource use (HRU) and costs in subjects with allergic rhinitis.

Methods:

REACT was a retrospective propensity score-matched cohort study using claims data from a German health insurance database (2007-2017), with up to 9 years of follow-up after AIT initiation. HRU and costs were evaluated for hospitalizations, ambulatory care visits, and prescriptions, in subjects who received AIT versus in matched controls with allergic rhinitis who had not received AIT, as well as for SCIT and SLIT tablets.

Results:

Across all 9 years, the subjects who received AIT had a significantly lower incidence of hospitalization than the controls did. Generally, proportions of subjects with ambulatory care visits and hospitalizations were lower, and length of hospitalization was shorter, for those receiving SLIT tablets than those who received SCIT. Total costs were significantly higher with AIT versus for the controls during the treatment period (years 1 to 3), driven by prescriptions and ambulatory care visits, but they were lower in years 4 to 9. During years 1 to 3, prescription costs were generally higher for SLIT tablets than for SCIT, whereas ambulatory care costs were numerically lower. In most years, hospitalization costs were numerically lower for SLIT tablets than for SCIT.

Conclusion:

Initial higher HRU and costs of AIT during the expected treatment period are offset in the long term. At-home administration of SLIT tablets may further reduce ambulatory care costs.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Health_economic_evaluation / Observational_studies / Risk_factors_studies Idioma: En Revista: J Allergy Clin Immunol Glob Año: 2024 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Health_economic_evaluation / Observational_studies / Risk_factors_studies Idioma: En Revista: J Allergy Clin Immunol Glob Año: 2024 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Estados Unidos